Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AADI NASDAQ:ENGN NASDAQ:ONCY NYSEAMERICAN:SER On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAADIAadi Bioscience$4.02-4.1%$4.29$1.21▼$3.81$99.28M0.68261,100 shs523,831 shsENGNenGene$1.92+0.5%$2.40$1.40▼$12.25$127.94M-0.281.00 million shs1.41 million shsONCYOncolytics Biotech$0.86-2.8%$0.89$0.77▼$1.51$105.06M1.091.07 million shs1.24 million shsSERSerina Therapeutics$2.17+11.3%$1.84$1.22▼$7.92$29.25M1.11127,173 shs99,607 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAADIAadi Bioscience0.00%+0.72%+0.96%+19.71%+110.55%ENGNenGene+7.30%+7.30%+16.46%-73.94%-50.77%ONCYOncolytics Biotech-2.10%-8.46%+5.26%-2.20%-2.31%SERSerina Therapeutics+2.63%-1.02%+3.72%-6.25%+194,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAADIAadi Bioscience$4.02-4.1%$4.29$1.21▼$3.81$99.28M0.68261,100 shs523,831 shsENGNenGene$1.92+0.5%$2.40$1.40▼$12.25$127.94M-0.281.00 million shs1.41 million shsONCYOncolytics Biotech$0.86-2.8%$0.89$0.77▼$1.51$105.06M1.091.07 million shs1.24 million shsSERSerina Therapeutics$2.17+11.3%$1.84$1.22▼$7.92$29.25M1.11127,173 shs99,607 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAADIAadi Bioscience0.00%+0.72%+0.96%+19.71%+110.55%ENGNenGene+7.30%+7.30%+16.46%-73.94%-50.77%ONCYOncolytics Biotech-2.10%-8.46%+5.26%-2.20%-2.31%SERSerina Therapeutics+2.63%-1.02%+3.72%-6.25%+194,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAADIAadi Bioscience 0.00N/AN/AN/AENGNenGene 2.14Hold$11.05475.28% UpsideONCYOncolytics Biotech 2.75Moderate Buy$8.50893.22% UpsideSERSerina Therapeutics 3.00Buy$8.00268.66% UpsideCurrent Analyst Ratings BreakdownLatest SER, ENGN, ONCY, and AADI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2026SERSerina Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$8.007/1/2026SERSerina Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$8.006/25/2026ONCYOncolytics Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/18/2026ENGNenGene Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeEqual Weight ➝ Underweight$3.006/16/2026ENGNenGene HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$6.00 ➝ $4.006/11/2026ONCYOncolytics Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/29/2026ONCYOncolytics Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/26/2026ONCYOncolytics Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.005/15/2026ENGNenGene Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/14/2026ENGNenGene UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$9.00 ➝ $2.005/8/2026ONCYOncolytics Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)(Data available from 7/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAADIAadi Bioscience$25.07M3.96N/AN/A$4.29 per share0.94ENGNenGeneN/AN/AN/AN/A$2.60 per shareN/AONCYOncolytics BiotechN/AN/AN/AN/A($0.04) per shareN/ASERSerina Therapeutics$130K250.38N/AN/A($0.46) per share-4.72Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAADIAadi Bioscience-$65.76M-$2.35N/AN/AN/A-246.06%-71.87%-57.28%N/AENGNenGene-$117.30M-$2.17N/AN/AN/AN/A-56.06%-45.64%9/14/2026 (Estimated)ONCYOncolytics Biotech-$28.76M-$0.31N/AN/AN/AN/A-2,185.97%-321.54%7/31/2026 (Estimated)SERSerina Therapeutics-$19.18MN/AN/AN/AN/AN/A-8,051.54%-155.08%N/ALatest SER, ENGN, ONCY, and AADI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/15/2026Q2 2026ENGNenGene-$0.48$0.43+$0.91$0.43N/AN/A5/14/2026Q1 2026ONCYOncolytics Biotech-$0.05-$0.08-$0.03-$0.08N/AN/A5/14/2026Q1 2026SERSerina TherapeuticsN/A-$0.58N/A-$0.58N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAADIAadi BioscienceN/AN/AN/AN/AN/AENGNenGeneN/AN/AN/AN/AN/AONCYOncolytics BiotechN/AN/AN/AN/AN/ASERSerina TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAADIAadi BioscienceN/A4.894.54ENGNenGene0.1012.5712.57ONCYOncolytics BiotechN/A1.381.38SERSerina Therapeutics0.244.184.18Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAADIAadi Bioscience52.08%ENGNenGene64.16%ONCYOncolytics Biotech6.82%SERSerina Therapeutics12.50%Insider OwnershipCompanyInsider OwnershipAADIAadi Bioscience37.30%ENGNenGene10.50%ONCYOncolytics Biotech0.10%SERSerina Therapeutics17.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAADIAadi Bioscience4024.70 million15.49 millionNo DataENGNenGene3166.99 million59.95 millionN/AONCYOncolytics Biotech30119.35 million119.24 millionNot OptionableSERSerina TherapeuticsN/A15.00 million12.34 millionN/ASER, ENGN, ONCY, and AADI HeadlinesRecent News About These CompaniesGannet BioChem and Serina Therapeutics Enter Development Partnership Supporting SER-252 ProgramJune 30, 2026 | globenewswire.comSerina Therapeutics Shareholders Approve Expanded Equity and GovernanceJune 24, 2026 | tipranks.comSerina Therapeutics (NYSEAMERICAN:SER) Director Acquires $17,700.00 in StockMay 27, 2026 | insidertrades.comSerina Therapeutics (NYSEAMERICAN:SER) Director Acquires $20,101.95 in StockMay 23, 2026 | insidertrades.comInsider-Backed PIPE Deal May Dilute Serina Therapeutics Shareholders and Heighten Governance RisksMay 16, 2026 | tipranks.comSerina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdatesMay 14, 2026 | globenewswire.comSerina Therapeutics to Present at the 5th LNP Formulation & Process Development SummitApril 7, 2026 | globenewswire.comSerina Therapeutics: Clinical Progress Overshadowed by Financial StrainApril 3, 2026 | aktiencheck.deASerina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance PlanApril 2, 2026 | globenewswire.comSerina Therapeutics Approaches Critical Clinical and Financial JunctureMarch 31, 2026 | aktiencheck.deAFunding the Fight: Serina Therapeutics' Parkinson's Pursuit Comes at a Steep CostMarch 27, 2026 | aktiencheck.deAInsider Selling: Serina Therapeutics (NYSEAMERICAN:SER) Insider Sells 6,500 Shares of StockMarch 26, 2026 | insidertrades.comSerina Therapeutics Reports Full Year 2025 Financial Results and Recent Business HighlightsMarch 25, 2026 | markets.businessinsider.comSerina Therapeutics CEO Steve Ledger to Present at the 38th Annual Roth ConferenceMarch 24, 2026 | quiverquant.comQSerina Therapeutics to Present at the 38th Annual Roth ConferenceMarch 24, 2026 | globenewswire.comInsider Selling: Serina Therapeutics (NYSEAMERICAN:SER) Insider Sells 39,000 Shares of StockMarch 21, 2026 | insidertrades.comSerina Therapeutics Secures Funding to Advance Parkinson's TreatmentMarch 19, 2026 | aktiencheck.deASerina Therapeutics (SER) stock surges over 39% after hours—here's whyMarch 19, 2026 | msn.comSerina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson’s DiseaseMarch 19, 2026 | markets.businessinsider.comSerina Therapeutics (SER) Stock Jumps 39% Following $63M Financing Deal and Leadership AnnouncementMarch 19, 2026 | blockonomi.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesCould a Tesla-SpaceX Merger Be Closer Than Investors Think?By Sam Quirke | June 17, 2026Why Oracle's 10% Drop May Be Telling the Wrong StoryBy Thomas Hughes | June 12, 2026Intel Is the Market's Most Mispriced AI HedgeBy Jeffrey Neal Johnson | June 10, 20265 Ways to Play Prime Day That Aren’t AmazonBy Thomas Hughes | June 23, 20262 Quantum Stocks Are Drawing Capital as AI Infrastructure Hits a WallBy Jeffrey Neal Johnson | June 18, 2026SER, ENGN, ONCY, and AADI Company DescriptionsAadi Bioscience NASDAQ:AADI$4.02 -0.17 (-4.06%) As of 07/6/2026Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.enGene NASDAQ:ENGN$1.92 +0.01 (+0.52%) Closing price 04:00 PM EasternExtended Trading$1.91 -0.01 (-0.31%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.Oncolytics Biotech NASDAQ:ONCY$0.86 -0.02 (-2.77%) Closing price 04:00 PM EasternExtended Trading$0.85 -0.01 (-0.79%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.Serina Therapeutics NYSEAMERICAN:SER$2.17 +0.22 (+11.28%) Closing price 04:10 PM EasternExtended Trading$2.12 -0.05 (-2.12%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Apple and Broadcom Forge a Decade-Long Silicon Fortress SK Hynix’s Nasdaq Listing Could Reset the AI Memory Trade The AI Chip Sell-Off Looks Scary, But the Real Story May Be Liquidity Palantir's CEO Just Called Out OpenAI and Anthropic Silicon Starvation: Amazon Feasts on Legacy GPUs GE Vernova’s Power Surge Turns the Grid Into an AI Trade 3 Quiet AI Revenue Accelerators With Sales Growth Outpacing Peers Abivax: Wall Street Catches Up to the Data Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
